Class matters: Sensitivity of BRAF-mutant melanoma to MAPK inhibition

Mutations in BRAF outside of the 600 codon (BRAF non-V600) occur across cancer types, including in 3-5% of melanomas. The optimal treatment strategies are not clear, but could include MEK inhibitors based on pre-clinical studies. Combining BRAF and MEK inhibitors in this population may provide additional benefit.

https://ift.tt/2LCF0zh